Results 251 to 260 of about 1,461,609 (326)

Single-domain antibodies for brain targeting [PDF]

, 2014
Lalatsa, Katerina, Moreira Leite, Diana
core   +1 more source

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade. [PDF]

Front Immunol
Bielski P, Barczyński J, Mikitiuk M, Myrcha M, Rykała K, Boon L, Gąsior W, Hec-Gałązka A, Holak TA, Sitar T.   +9 more
europepmc   +1 more source

Multidisciplinary assessment of patients with extensive stage small cell lung cancer: A geriatric tumor board

CA: A Cancer Journal for Clinicians, EarlyView.
Humera Khurshid, Sakeena Raza, Robert Brunault, Brittany Duffy, Michael Kavanaugh   +4 more
wiley   +1 more source

Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database

Cancer Medicine, Volume 14, Issue 15, August 2025.
ABSTRACT Background Early (often continuous) treatment of multiple myeloma (MM) with lenalidomide has become common practice, leading to an increase in lenalidomide‐refractory disease. Methods We report real‐world treatment patterns, health care resource utilization (HCRU), and outcomes for patients with lenalidomide‐refractory MM using data from Optum
Binod Dhakal, Hermann Einsele, Jordan M. Schecter, William Deraedt, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Sandhya Nair, Nirosha Elsem Varghese, Jianming He, Akshay Kharat, Seina Lee, Patricia Cost, Ravi Potluri, Mythili Koneru, Nitin Patel, Erika Florendo, Paula Rodriguez‐Otero, Kwee Yong   +18 more
wiley   +1 more source

A multifunctional T-cell engager containing CD80 enhances prostate cancer treatment. [PDF]

Cancer Immunol Immunother
Nie D, Jiang Y, Li H, Zhang K, Li Z, Lu T, Li Y, Han D, Shi C, Xing N, Yang F, Wen W, Qin W.   +12 more
europepmc   +1 more source

Treating EGFR‐mutant nonsmall cell lung cancer is no longer a one‐size‐fits‐all approach

CA: A Cancer Journal for Clinicians, EarlyView.
Lauren J. Antrim, Jyoti Malhotra
wiley   +1 more source

Dose Selection for DuoBody®‐CD40x4‐1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 418-427, August 2025.
Optimizing target engagement for bispecific antibodies (bsAbs) is challenging, as bsAbs bind to two different targets in vivo to form a trimolecular complex (trimer), and likely display a bell‐shaped concentration–response curve. bsAbs trimer formation is expected to be related to efficacy and safety, and determining the dose level at which it is ...
Gaurav Bajaj, Dmitry Shchelokov, Oleg Demin Jr, Homer C. Adams 3rd, Yan Feng, Leonid Gibiansky, Saskia van der Lee, Anandhi Johri, Merzu Belete, Alexander Muik, Porntula Panorchan, Özlem Türeci, Uğur Sahin, Tahamtan Ahmadi, Manish Gupta, Oleg Demin, Craig Thalhauser   +16 more
wiley   +1 more source

Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial. [PDF]

Cell Discov
Wu Y, Li Y, Zhang P, Guo S, Yuan F, Liu V, Yu T, Lin F, Yang N, Tu C, Lu H, Ying T, Li X.   +12 more
europepmc   +1 more source

The physiological limits of bispecific monoclonal antibody tissue targeting specificity. [PDF]

MAbs
Sepp A, Stader F, Derbalah A, Liu C, Zyla A, Gardner I, Jamei M.   +6 more
europepmc   +1 more source